Vivos Inc. reported encouraging results from the initial phase of its human clinical trial for RadioGel Precision Radionuclide Therapy. The first five patients treated demonstrated the safety of the therapy, meeting the criteria outlined in the Clinical Study Plan. This included confirmation via PET imaging that the Yttrium-90 isotope remained precisely at the point of injection.
No adverse events were reported by any of the initial five patients since their treatment date. This positive safety profile is a critical early indicator for the novel cancer treatment. The company also noted 30-day PET/F-18 imaging of a local patient, further supporting the therapy's localized effect.
These early results are significant for Vivos Inc. as they reinforce the safety profile of RadioGel, which is crucial for its continued development and regulatory pathway. The company is actively pursuing human clinical trials in India and plans to use this data to support its Investigational Device Exemption (IDE) submission to the FDA for studies in the United States.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.